GlassScriptPhysician profile
Timothy C Spears
NPI 1639173156
$4,851.49
in general payments reported to CMS, 2019-2025
39 companies · $564 in 2025
The $564 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $589 · 2021: $1,050 · 2022: $858 · 2023: $598 · 2024: $634 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770 · Education: $26.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.80 |
| Education | $26.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $900.67 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $746.79 | 2021-2025 | Vraylar, Creon, Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $595.17 | 2021-2025 | Caplyta |
| Lilly USA, LLC | $302.56 | 2019-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $275.81 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.78 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $213.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $154.06 | 2019-2020 | |
| Glaxosmithkline, LLC. | $131.65 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Allergan, INC. | $129.34 | 2019-2020 | |
| Eisai INC. | $116.13 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.65 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $86.69 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $72.39 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $71.42 | 2024 | Fanapt, Hetlioz |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.